, Volume 17, Issue 4, pp 636-644

SSAT/AHPBA Joint Symposium on Evaluation and Treatment of Benign Liver Lesions

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Introduction

To treat or not to treat benign liver lesions is an important clinical issue because some can be life threatening, whereas most are not. The risk–benefit ratio for treatment must be evaluated for each patient on the basis of radiologic, biologic, and clinical characteristics. In 2012, the Society for Surgery of the Alimentary Tract and the Americas Hepato-Pancreato-Biliary Association held a joint symposium at which experts addressed the evaluation and treatment of benign liver lesions. Harmeet Kaur, MD, and Evelyne Loyer, MD, of the Department of Diagnostic Radiology at MD Anderson Cancer Center discuss advances in imaging of benign liver lesions. Valérie Paradis, MD, of the Hôpital Beaujon in Clichy, France, discusses the pathology and biology of hepatocellular adenoma (HCA). Michael G. House, MD, of the Indiana University School of Medicine discusses the treatment of complex cysts, polycystic liver disease, Caroli’s disease, and cystadenoma. Finally, Yun Shin Chun, MD, o

This paper was originally presented as part of the SSAT/AHPBA Joint Symposium: Evaluation and Treatment of Benign Liver Neoplasms at the SSAT 53rd annual meeting, May 2012, in San Diego, California.
The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant CA016672